OQROGet OQRO Pro
Insider trade

Abbott Laboratories (ABT)Director bought ~$927K

Daniel J Starks, Director at Abbott Laboratories, bought ~$927K of Abbott Laboratories shares.

~$927K
Approx. value · 10K sh @ $92.65
6.75M
Holds after · shares reported
Traded
Apr 27, 2026
Filed
Apr 28, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Feb 10, 2026CongressDisclosed partial sale of ABT — reported range $1,001 - $15,000
  2. Feb 23, 2026Company filing · Form 8-K · Material agreementSigned an important agreement
  3. Mar 2, 2026Insider · 6 peopleInsiders: 6 sales (~$485K)
  4. Mar 9, 2026Company filing · Form 8-K · Material agreement, New debtSigned an important agreement, and took on new debt or obligations
  5. Mar 13, 2026FDAFDA device clearance: Amplatzer™ Trevisio™ Intravascular Delivery System; 9-ATV06F45/609-ATV07F45/609-ATV07F45/809-ATV08F45/609-ATV08F45/809-ATV09F45/809-ATV10F45/809-ATV12F45/80
  6. Mar 19, 2026CongressDisclosed purchase of ABT — reported range $1,001 - $15,000
  7. Mar 26, 20265% stakeThe Vanguard Group reported a passive stake (13G)
  8. Mar 27, 2026CongressDisclosed sale of ABT — reported range $15,001 - $50,000
  9. Apr 16, 2026Company filing · Form 8-K · ResultsReported its results
  10. Apr 16, 2026FDAFDA device clearance: Disposable Radiofrequency Cannula
  11. Apr 16, 2026CongressDisclosed sale of ABT — reported range $15,001 - $50,000
  12. Apr 20, 2026FDAFDA device clearance: EnSite™ X EP System
  13. Apr 23, 2026Insider · 1 day before an 8-KCFO purchased ~$201K of ABT shares in the open market
  14. Apr 24, 2026Company filing · Form 8-K · Executive change, Bylaws or charterChanged a top executive or board member, and changed its bylaws, charter or fiscal year (and 1 more item)“On April 24, 2026, Kevin Conroy was named to the Abbott Laboratories’ (“Abbott”) Board of Directors. On April 24, 2026, Abbott shareholders approved the adoption of the Abbott Laboratories 2026 Incentive Stock Program (the “2026 Program”) at the Annual Meeting of Shareholders.”
  15. Apr 24, 2026FDAFDA device clearance: OPTIS Mobile Next Imaging System (1014932); OPTIS Integrated Next Imaging System (1014933); Ultreon 3.0 Software Upgrade Kit (ULTR300001)
  16. Apr 24, 2026FDAFDA device clearance: Amplatzer TorqVue Delivery System
  17. Apr 27, 2026 · this disclosureInsider · Their largest buy since 2018Director purchased ~$927K of ABT shares in the open market

What came next

  1. Apr 28, 2026FDAFDA device clearance: Anti-HCV Next
  2. Apr 29, 20265% stakeVanguard Capital Management reported a passive stake (13G) of 7.5%
  3. May 7, 2026Insider · Their largest buy since 2019Director purchased ~$174K of ABT shares in the open market
  4. May 12, 2026FDARecall: Merlin" Patient Care System (PCS) software Merlin" PCS 3650 programmer Model 3330 software
  5. May 12, 2026CongressDisclosed sale of ABT — reported range $1,001 - $15,000
  6. May 15, 2026CongressDisclosed sale of ABT — reported range $1,001 - $15,000
  7. May 27, 2026Government · Federal Register noticeDrugs for Human Use; Drug Efficacy Study Implementation: Estrogen-Androgen Fixed-Combination Drug Products; Syntest D.S. and Syntest H.S. Tablets; Withdrawal of Hearing Requests; Final Resolution of Drug Efficacy Study Implementation 7661
  8. May 27, 2026CongressDisclosed partial sale of ABT — reported range $1,001 - $15,000
  9. Jun 12, 2026Congress · 1 personMembers of Congress: 2 purchases
  10. Jun 16, 2026CongressDisclosed purchase of ABT — reported range $1,001 - $15,000
  11. Jun 17, 2026FDAFDA device clearance: Amplatzer TorqVue Exchange System
  12. Jul 2, 2026FDAFDA device clearance: Amplatzer TorqVue LP Delivery System; Amplatzer TorqVue LP Catheter
  13. Jul 7, 2026Government · Federal Register proposed ruleMedicare Program: Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems; and Quality Reporting Programs; Including the Hospital Outpatient Quality Reporting Program and Ambulatory Surgical Center Quality Program; Request for Information on Strengthening the Standardization and Comparability of Hospital Price Transparency (HPT) Data; Prior Authorization; Accrediting Organization (AO) Deeming for Emergency Medical Treatment and Labor Act (EMTALA); and Notices of Closure of Teaching Hospitals and Opportunities To Apply for Available Slots
  14. Jul 8, 2026CongressDisclosed sale of ABT — reported range $1,001 - $15,000
  15. Jul 14, 2026CongressDisclosed sale of ABT — reported range $15,001 - $50,000
  16. Jul 15, 2026FDAFDA device clearance: EnSite™ X EP System
  17. Jul 16, 2026Company filing · Form 8-K · ResultsReported its results
  18. Jul 17, 2026CongressDisclosed sale of ABT — reported range $1,001 - $15,000
  19. Jul 30, 2026CongressDisclosed sale of ABT — reported range $1,001 - $15,000
  20. Aug 6, 2026Government · Federal Register noticeForeign-Trade Zone (FTZ) 39, Notification of Proposed Production Activity; Abbott Laboratories; (Diagnostic Medical Devices); Irving, Texas
View the official recordSEC Form 4

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Abbott Laboratories

For Abbott Laboratories, OQRO holds 5 insider filings (SEC Form 4 or Form 144), 4 Congress trade reports and 82 fund holdings reports (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its ABT page.

Other recent filings by Daniel J Starks, Director

The full history of Daniel J Starks, Director is on the profile page.

How this filing works

Other disclosures at Abbott Laboratories

Everything OQRO holds on this company is on its ABT page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

Unlock OQRO ProAlready have an account? Log in

OQRO Pro is a paid subscription. You see the price before you pay

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data